AGIO (Agios Pharmaceuticals) Quality Rank

View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Agios Pharmaceuticals Quality Rank Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

0HB0:UK 8AP:Germany 8AP:Germany

Address

88 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Executives

Tsveta Milanova	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
James William Burns	officer: Chief Legal Officer	C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Washburn Theodore James Jr.	officer: Principal Accounting Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
David Scadden	director	88 SIDNEY STREET, CAMBRIDGE MA 02139
Rahul D. Ballal	director	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Brian Goff	director, officer: Chief Executive Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens	officer: Chief Medical Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse	director	C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Kaye I Foster-cheek	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
David P Schenkein	director, 10 percent owner, officer: Chief Executive Officer	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Catherine E. Owen	director	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Jeffrey D Capello	director	C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Richa Poddar	officer: Chief Commercial Officer	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139